The Role of Psychostimulants in the Management of Refractory Catatonia: A Comprehensive Review of Case Reports
Background/Objectives: Catatonia is a neuropsychiatric syndrome characterised by motor, behavioural, and affective abnormalities and is frequently associated with mood disorders, particularly major depressive and bipolar disorders. Although benzodiazepines and electroconvulsive therapy are considered first-line treatments, a substantial proportion of patients show partial or no response, especially in chronic, affective, or medically complex presentations. Contemporary neurobiological models implicate dysfunction across multiple neurotransmitter systems, including GABAergic, glutamatergic, and dopaminergic pathways, as well as disturbances in cortico-striato-thalamo-cortical circuits involved in psychomotor control and arousal regulation. Within this framework, psychostimulants may exert therapeutic effects by enhancing dopaminergic and noradrenergic transmission, thereby modulating frontal–striatal networks and facilitating behavioural activation and motor initiation. Evidence from conditions characterised by psychomotor slowing, apathy, and impaired behavioural initiation provides a neurophysiological rationale for their adjunctive use in selected cases of catatonia, particularly when associated with mood disorders. However, there is a dearth of empirical data, with the evidence largely confined to case reports, hence the need for comprehensive reviews of cases and controlled studies to clarify the role of psychostimulants and to explore drug combinations in the treatment of catatonia. Methods: We conducted a comprehensive review of case reports on 22-October-2026 on PubMed, Scopus, PsycInfo/PsycArticles, and Web of Science. Results: We included 9 studies. Psychostimulants were usually helpful in inducing rapid symptoms resolution of catatonia. Conclusions: Psychostimulants may be used in cases of catatonia and provide rapid improvement. Future longitudinal, double-blind designs are likely to allow reliably assessing the value of psychostimulants in catatonia.
Authors
- Delfina Janiri (ORCID: https://orcid.org/0000-0003-2485-6121)
- Silvia Montanari (ORCID: https://orcid.org/0009-0007-0266-0204)
- Alessio Simonetti (ORCID: https://orcid.org/0000-0002-6963-7494)
- Gabriele Sani (ORCID: https://orcid.org/0000-0002-9767-8752)
- Stella Margoni (ORCID: https://orcid.org/0000-0002-0562-8134)
- Georgios Demetrios Kotzalidis (ORCID: https://orcid.org/0000-0002-0281-6324)
- Alexia Emilia Koukopoulos (ORCID: https://orcid.org/0000-0002-7004-5007)
- Giovanni Bartolucci (ORCID: https://orcid.org/0009-0003-4557-5369)
- Lorenzo Moccia (ORCID: https://orcid.org/0000-0003-3176-6060)
- Luca Onori
- Mario Pinto (ORCID: https://orcid.org/0000-0001-8254-9299)
- Michele Pellegrino
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Baylor College of Medicine (US)
- Agostino Gemelli University Polyclinic (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/ph19111836
- Primary Topic
- Electroconvulsive Therapy Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00